NASDAQ:APTO - Aptose Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.44 +0.10 (+2.99 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$3.44
Today's Range$3.3302 - $3.59
52-Week Range$1.00 - $3.97
Volume492,124 shs
Average Volume178,703 shs
Market Capitalization$113.18 million
P/E Ratio-6.62
Dividend YieldN/A
Beta2.38

About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences logoAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828

Debt

Debt-to-Equity RatioN/A
Current Ratio7.51
Quick Ratio7.51

Price-To-Earnings

Trailing P/E Ratio-6.62
Forward P/E Ratio-4.78
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book7.82

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-136.61%
Return on Assets-119.69%

Miscellaneous

Employees23
Outstanding Shares32,900,000

Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings data on Tuesday, March, 27th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. View Aptose Biosciences' Earnings History.

What price target have analysts set for APTO?

4 brokers have issued twelve-month target prices for Aptose Biosciences' shares. Their predictions range from $6.00 to $7.00. On average, they expect Aptose Biosciences' stock price to reach $6.3333 in the next twelve months. View Analyst Ratings for Aptose Biosciences.

Who are some of Aptose Biosciences' key competitors?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

Has Aptose Biosciences been receiving favorable news coverage?

Press coverage about APTO stock has trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aptose Biosciences earned a news impact score of 0.21 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 44.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ladenburg Thalmann Financial Services Inc. (0.19%). View Institutional Ownership Trends for Aptose Biosciences.

Which institutional investors are buying Aptose Biosciences stock?

APTO stock was bought by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for Aptose Biosciences.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $3.44.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $113.18 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 23 workers across the globe.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]


MarketBeat Community Rating for Aptose Biosciences (APTO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aptose Biosciences (NASDAQ:APTO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Aptose Biosciences in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 84.11%. The high price target for APTO is $7.00 and the low price target for APTO is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.3333$6.3333$6.00$5.3333
Price Target Upside: 84.11% upside75.93% upside233.33% upside180.70% upside

Aptose Biosciences (NASDAQ:APTO) Consensus Price Target History

Price Target History for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2018HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
4/16/2018Roth CapitalSet Price TargetBuy$6.00LowView Rating Details
11/15/2017Canaccord GenuitySet Price TargetBuy$7.00N/AView Rating Details
6/8/2017Rodman & RenshawInitiated CoverageNeutral ➝ NeutralHighView Rating Details
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 ➝ $12.00N/AView Rating Details
6/9/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Aptose Biosciences (NASDAQ:APTO) Earnings History and Estimates Chart

Earnings by Quarter for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.7 EPS

Aptose Biosciences (NASDAQ APTO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2018Q4 2017($0.11)($0.12)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.13)($0.11)ViewN/AView Earnings Details
8/8/2017Q2($0.18)($0.11)ViewListenView Earnings Details
5/11/2017Q1 2017($0.19)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.19)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.36)($0.24)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.32)($0.36)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.30)($0.31)ViewN/AView Earnings Details
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.31)($0.22)ViewN/AView Earnings Details
5/5/2015Q1 2015($0.31)($0.25)ViewN/AView Earnings Details
3/3/2015Q4 2014($0.31)($0.25)ViewN/AView Earnings Details
11/5/2014Q3 2014($0.32)ViewN/AView Earnings Details
7/15/2014Q2 2014($0.24)($0.48)ViewN/AView Earnings Details
4/10/2014Q1 2014($0.72)($0.48)ViewN/AView Earnings Details
1/7/2014Q4 2013($0.72)ViewN/AView Earnings Details
10/15/2013Q3 2013($0.36)ViewN/AView Earnings Details
7/15/2013Q2 2013($0.36)ViewN/AView Earnings Details
4/12/2013Q1 2013($0.36)ViewN/AView Earnings Details
1/14/2013Q4 2012($0.48)ViewN/AView Earnings Details
10/15/2012Q3 2012($0.36)ViewN/AView Earnings Details
8/8/2012Q2 2012$0.60ViewN/AView Earnings Details
4/12/2012Q1 2012($0.58)ViewN/AView Earnings Details
1/13/2012Q4 2011($0.82)ViewN/AView Earnings Details
11/11/2011Q3 2011($0.76)ViewN/AView Earnings Details
8/26/2011Q2 2011($0.73)ViewN/AView Earnings Details
1/14/2011Q4 2010($1.34)ViewN/AView Earnings Details
10/15/2010Q3 2010($1.38)ViewN/AView Earnings Details
8/30/2010Q2 2010($2.16)ViewN/AView Earnings Details
1/14/2009Q4 2008$4.41ViewN/AView Earnings Details
10/9/2008Q3 2008$3.24ViewN/AView Earnings Details
4/14/2008Q1 2008$6.49ViewN/AView Earnings Details
1/8/2008Q4 2007($4.69)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aptose Biosciences (NASDAQ:APTO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aptose Biosciences (NASDAQ APTO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 1.05%
Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
Institutional Ownership by Quarter for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ APTO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Aptose Biosciences (NASDAQ APTO) News Headlines

Source:
DateHeadline
Aptose Approaching The Clinic With 2 Very Interesting AssetsAptose Approaching The Clinic With 2 Very Interesting Assets
seekingalpha.com - May 17 at 8:31 AM
Aptose Biosciences (APTO) Lowered to Sell at Zacks Investment ResearchAptose Biosciences (APTO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 5:31 PM
Aptose Biosciences Inc. (APTO) Expected to Post Earnings of -$0.13 Per ShareAptose Biosciences Inc. (APTO) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 15 at 10:11 AM
Aptose Biosciences (APTO) PT Set at $6.00 by HC WainwrightAptose Biosciences (APTO) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - May 14 at 12:42 PM
Aptose Biosciences (APTO) Reports Q1 Loss of $0.23Aptose Biosciences (APTO) Reports Q1 Loss of $0.23
www.streetinsider.com - May 11 at 9:16 AM
Aptose Biosciences (APTO) CEO William Rice on Q1 2018 Results - Earnings Call TranscriptAptose Biosciences' (APTO) CEO William Rice on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:16 AM
Aptose Reports Results for the First Quarter Ended March 31, 2018Aptose Reports Results for the First Quarter Ended March 31, 2018
finance.yahoo.com - May 10 at 5:22 PM
Aptose Biosciences: 1Q Earnings SnapshotAptose Biosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:22 PM
Aptose Biosciences (APTO) Raised to "Hold" at ValuEngineAptose Biosciences (APTO) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 8 at 11:54 PM
HC Wainwright Analysts Give Aptose Biosciences (APTO) a $6.00 Price TargetHC Wainwright Analysts Give Aptose Biosciences (APTO) a $6.00 Price Target
www.americanbankingnews.com - May 7 at 12:57 PM
LifeSci Advisors Announces 14th Board Appointment Through Its Board Placement InitiativeLifeSci Advisors Announces 14th Board Appointment Through Its Board Placement Initiative
globenewswire.com - May 1 at 5:22 PM
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018
finance.yahoo.com - May 1 at 8:06 AM
Aptose Biosciences Inc. (APTO) Receives Average Rating of "Hold" from AnalystsAptose Biosciences Inc. (APTO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 1:34 AM
Zacks: Brokerages Anticipate Aptose Biosciences Inc. (APTO) to Announce -$0.12 Earnings Per ShareZacks: Brokerages Anticipate Aptose Biosciences Inc. (APTO) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - April 27 at 7:20 PM
BRIEF-Aptose Announces Appointment Of Caroline M. Loewy To Board Of DirectorsBRIEF-Aptose Announces Appointment Of Caroline M. Loewy To Board Of Directors
www.reuters.com - April 25 at 8:38 AM
Form 6-K Aptose Biosciences Inc. For: Apr 25Form 6-K Aptose Biosciences Inc. For: Apr 25
www.streetinsider.com - April 25 at 8:38 AM
Lorus Therapeutics (APTO) Lifted to Sell at ValuEngineLorus Therapeutics (APTO) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 19 at 11:32 AM
Zacks Investment Research Lowers Lorus Therapeutics (APTO) to HoldZacks Investment Research Lowers Lorus Therapeutics (APTO) to Hold
www.americanbankingnews.com - April 16 at 4:48 PM
Lorus Therapeutics (APTO) Given a $6.00 Price Target at HC WainwrightLorus Therapeutics (APTO) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 16 at 1:54 PM
Lorus Therapeutics (APTO) Given a $6.00 Price Target by Roth Capital AnalystsLorus Therapeutics (APTO) Given a $6.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - April 16 at 1:21 PM
-$0.12 Earnings Per Share Expected for Lorus Therapeutics, Inc. (APTO) This Quarter-$0.12 Earnings Per Share Expected for Lorus Therapeutics, Inc. (APTO) This Quarter
www.americanbankingnews.com - April 10 at 7:21 PM
Head-To-Head Survey: Lorus Therapeutics (APTO) versus Adverum Biotechnologies (ADVM)Head-To-Head Survey: Lorus Therapeutics (APTO) versus Adverum Biotechnologies (ADVM)
www.americanbankingnews.com - April 10 at 7:09 PM
Lorus Therapeutics (APTO) Upgraded to Buy at Zacks Investment ResearchLorus Therapeutics (APTO) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 5:52 PM
Lorus Therapeutics (APTO) "Buy" Rating Reiterated at Roth CapitalLorus Therapeutics' (APTO) "Buy" Rating Reiterated at Roth Capital
www.americanbankingnews.com - April 6 at 12:28 PM
Lorus Therapeutics (APTO) Downgraded to Hold at Zacks Investment ResearchLorus Therapeutics (APTO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM
Lorus Therapeutics, Inc. (APTO) Receives Average Recommendation of "Hold" from BrokeragesLorus Therapeutics, Inc. (APTO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 5 at 1:21 AM
Lorus Therapeutics (APTO) Upgraded by ValuEngine to "Sell"Lorus Therapeutics (APTO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 4 at 12:02 AM
Lorus Therapeutics (APTO) Upgraded at ValuEngineLorus Therapeutics (APTO) Upgraded at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM
Will Aptose Biosciences Inc’s (TSE:APS) Earnings Grow In The Next Couple Of Years?Will Aptose Biosciences Inc’s (TSE:APS) Earnings Grow In The Next Couple Of Years?
finance.yahoo.com - April 3 at 8:20 AM
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceAptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 3 at 8:20 AM
Lorus Therapeutics (APTO) Cut to "Hold" at Zacks Investment ResearchLorus Therapeutics (APTO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:40 PM
Form SUPPL Aptose Biosciences Inc.Form SUPPL Aptose Biosciences Inc.
www.streetinsider.com - March 29 at 8:24 AM
ValuEngine Lowers Aptose Biosciences (APTO) to Strong SellValuEngine Lowers Aptose Biosciences (APTO) to Strong Sell
www.americanbankingnews.com - March 28 at 10:22 PM
Aptose Biosciences (APTO) Lifted to "Buy" at Zacks Investment ResearchAptose Biosciences (APTO) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 5:28 PM
Aptose Bio inks at-the-market stock sales agreement with CantorAptose Bio inks at-the-market stock sales agreement with Cantor
seekingalpha.com - March 28 at 5:20 PM
Windtree Therapeutics (WINT) & Aptose Biosciences (APTO) Head-To-Head ComparisonWindtree Therapeutics (WINT) & Aptose Biosciences (APTO) Head-To-Head Comparison
www.americanbankingnews.com - March 26 at 1:09 PM
Aptose Biosciences Inc (APTO) Expected to Post Earnings of -$0.11 Per ShareAptose Biosciences Inc (APTO) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 24 at 9:24 PM
Aptose Biosciences (APTO) Downgraded by Zacks Investment ResearchAptose Biosciences (APTO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Aptose Biosciences (APTO) Raised to "Buy" at Zacks Investment ResearchAptose Biosciences (APTO) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 5:56 PM
Aptose Biosciences (APTO) Upgraded to Sell at ValuEngineAptose Biosciences (APTO) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 13 at 11:28 PM
Aptose Biosciences Inc (APTO) Given Average Recommendation of "Hold" by AnalystsAptose Biosciences Inc (APTO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 11 at 1:38 AM
Form F-10/A Aptose Biosciences Inc.Form F-10/A Aptose Biosciences Inc.
www.streetinsider.com - March 8 at 5:25 PM
Aptose Biosciences (APTO) Reports Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM OncologyAptose Biosciences (APTO) Reports Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
www.streetinsider.com - March 8 at 9:32 AM
Aptose Biosciences (APTO) Given a $6.00 Price Target by HC Wainwright AnalystsAptose Biosciences (APTO) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 7 at 6:56 PM
 Analysts Anticipate Aptose Biosciences Inc (APTO) to Announce -$0.13 EPS Analysts Anticipate Aptose Biosciences Inc (APTO) to Announce -$0.13 EPS
www.americanbankingnews.com - March 7 at 3:18 PM
Aptose to Participate in Upcoming Investor Conferences In March 2018Aptose to Participate in Upcoming Investor Conferences In March 2018
feeds.benzinga.com - March 6 at 7:45 AM
Aptose Biosciences (APTO) Downgraded to "Strong Sell" at ValuEngineAptose Biosciences (APTO) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 5 at 12:12 AM
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
finance.yahoo.com - February 26 at 5:17 PM
Critical Survey: Aptose Biosciences (APTO) vs. Idera Pharmaceuticals (IDRA)Critical Survey: Aptose Biosciences (APTO) vs. Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - February 23 at 3:16 AM
Comparing Arena Pharmaceuticals (ARNA) and Aptose Biosciences (APTO)Comparing Arena Pharmaceuticals (ARNA) and Aptose Biosciences (APTO)
www.americanbankingnews.com - February 17 at 9:12 PM

SEC Filings

Aptose Biosciences (NASDAQ:APTO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aptose Biosciences (NASDAQ:APTO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aptose Biosciences (NASDAQ APTO) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.